comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 17:42:41 - browse：838

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： New lesbian bars spark hope amid disappearing LGBTQ+ spaces

knowledge

WSS

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Synthetic human embryos? Researchers say term is overblown

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Canadians with cystic fibrosis outlive Americans by a decade

Brazil's Jair Bolsonaro is barred from running for office until 2030

UpToDate has a racism problem: Dr. Stanley Goldfarb

hotspot

comprehensive

knowledge

Supreme Court strikes down use of affirmative action

The biotech scorecard for Q3: 15 stock

Psychedelics group wrestles with new pharma identity

Medical experts exlpore how to eliminate bias in clinical algorithms

Medical records are filled with copy

Why do we get seasonal allergies?

Heart attack and stroke risk calculators need revising

Brazil's Jair Bolsonaro is barred from running for office until 2030

Heart attack and stroke risk calculators need revising

Security flaws in third

hotspot

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Lupron, used to halt puberty in children, may cause lasting health problems

Tuskegee Airman Raymond Cassagnol dies at 102

Beware reading your test results before your doctor does

Dexcom's push to bring CGM to type 2 diabetes patients

Vertex cell therapy lets patients with type 1 diabetes stop insulin

entertainment

focus

leisure time

entertainment